Recently Featured

Vertex Pharmaceuticals Plans New Research Facility at Harwell Science Campus

October 30, 2026
Vertex Pharmaceuticals plans to establish a 155,000-square-foot research facility at the Harwell Science and Innovation Campus in Oxfordshire, England, expanding its research and development footprint within the region’s life sciences sector. Construction is expected to begin in early 2027, subject to planning and regulatory approvals. The proposed facility will be located next to the new…
Sugammadex generics cut Merck's Bridion sales from $497M to $144M in one quarter. Who gained, who paid, and what it means for API sourcing.

Sugammadex Generics Wipe $353M Off Merck’s Bridion in One Quarter

October 30, 2026
Merck & Co., Inc. sold $497 million of Bridion (sugammadex) in the second quarter of 2026. One quarter and four US generic launches later, it sold $144 million, and the sugammadex generics that took the business are selling vials for a fraction of what the brand charged. That is the patent cliff in its cleanest…

EMA Office Closure on All Souls’ Day, 2 November

October 30, 2026
The European Medicines Agency (EMA) will be closed on Monday, 2 November, in observance of All Souls’ Day. This closure underscores the agency’s commitment to acknowledging significant cultural observances, which can impact operational schedules. The EMA will resume normal operations at 08:30 on Tuesday, 3 November, ensuring that regulatory processes continue without interruption following the…

UK Budget Light on Life Sciences but More Doors Open for Biotech Startups

October 30, 2026
In a recent announcement, the UK government unveiled its Autumn Budget, which has drawn a mixed response from the life sciences sector. The budget appears to prioritize broader business scaling initiatives over direct support for life sciences, leading to concerns among industry stakeholders about the potential impact on innovation and research funding. While the lack…

Ongoing Cases